265 related articles for article (PubMed ID: 20142330)
1. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.
Contreras CM; Akbay EA; Gallardo TD; Haynie JM; Sharma S; Tagao O; Bardeesy N; Takahashi M; Settleman J; Wong KK; Castrillon DH
Dis Model Mech; 2010; 3(3-4):181-93. PubMed ID: 20142330
[TBL] [Abstract][Full Text] [Related]
2. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Cheng H; Liu P; Zhang F; Xu E; Symonds L; Ohlson CE; Bronson RT; Maira SM; Di Tomaso E; Li J; Myers AP; Cantley LC; Mills GB; Zhao JJ
Cancer Res; 2014 Jan; 74(1):15-23. PubMed ID: 24322983
[TBL] [Abstract][Full Text] [Related]
3. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM
PLoS Genet; 2012; 8(8):e1002906. PubMed ID: 22916036
[TBL] [Abstract][Full Text] [Related]
4. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.
Contreras CM; Gurumurthy S; Haynie JM; Shirley LJ; Akbay EA; Wingo SN; Schorge JO; Broaddus RR; Wong KK; Bardeesy N; Castrillon DH
Cancer Res; 2008 Feb; 68(3):759-66. PubMed ID: 18245476
[TBL] [Abstract][Full Text] [Related]
5. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
6. LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment.
Peña CG; Nakada Y; Saatcioglu HD; Aloisio GM; Cuevas I; Zhang S; Miller DS; Lea JS; Wong KK; DeBerardinis RJ; Amelio AL; Brekken RA; Castrillon DH
J Clin Invest; 2015 Nov; 125(11):4063-76. PubMed ID: 26413869
[TBL] [Abstract][Full Text] [Related]
7. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
Bajwa P; Nielsen S; Lombard JM; Rassam L; Nahar P; Rueda BR; Wilkinson JE; Miller RA; Tanwar PS
Oncotarget; 2017 Jan; 8(5):7265-7275. PubMed ID: 27980219
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of mTOR activity through LKB1 inactivation.
Zhou W; Marcus AI; Vertino PM
Chin J Cancer; 2013 Aug; 32(8):427-33. PubMed ID: 23668926
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Chiu CW; Nozawa H; Hanahan D
J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
[TBL] [Abstract][Full Text] [Related]
10. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
11. An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.
Mirantes C; Eritja N; Dosil MA; Santacana M; Pallares J; Gatius S; Bergadà L; Maiques O; Matias-Guiu X; Dolcet X
Dis Model Mech; 2013 May; 6(3):710-20. PubMed ID: 23471917
[TBL] [Abstract][Full Text] [Related]
12. MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT.
Yoo JY; Kang HB; Broaddus RR; Risinger JI; Choi KC; Kim TH
BMC Cancer; 2018 May; 18(1):605. PubMed ID: 29843645
[TBL] [Abstract][Full Text] [Related]
13. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.
Shackelford DB; Vasquez DS; Corbeil J; Wu S; Leblanc M; Wu CL; Vera DR; Shaw RJ
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11137-42. PubMed ID: 19541609
[TBL] [Abstract][Full Text] [Related]
14. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
Carretero J; Shimamura T; Rikova K; Jackson AL; Wilkerson MD; Borgman CL; Buttarazzi MS; Sanofsky BA; McNamara KL; Brandstetter KA; Walton ZE; Gu TL; Silva JC; Crosby K; Shapiro GI; Maira SM; Ji H; Castrillon DH; Kim CF; García-Echeverría C; Bardeesy N; Sharpless NE; Hayes ND; Kim WY; Engelman JA; Wong KK
Cancer Cell; 2010 Jun; 17(6):547-59. PubMed ID: 20541700
[TBL] [Abstract][Full Text] [Related]
15. Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma.
McCampbell AS; Harris HA; Crabtree JS; Winneker RC; Walker CL; Broaddus RR
Cancer Prev Res (Phila); 2010 Mar; 3(3):290-300. PubMed ID: 20179297
[TBL] [Abstract][Full Text] [Related]
16. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.
Zhou C; Gehrig PA; Whang YE; Boggess JF
Mol Cancer Ther; 2003 Aug; 2(8):789-95. PubMed ID: 12939469
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
